Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5TT7

Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)

Summary for 5TT7
Entry DOI10.2210/pdb5tt7/pdb
Related5TR6
DescriptorTyrosine-protein kinase SYK, 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (3 entities in total)
Functional Keywordsinhibitor, kinase, leukemia, lymphoma, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (Human)
Cellular locationCell membrane : P43405
Total number of polymer chains1
Total formula weight34050.27
Authors
Yano, J.,Jennings, A.,Lam, B.,Hoffman, I.D. (deposition date: 2016-11-01, release date: 2016-11-30, Last modification date: 2024-03-06)
Primary citationLam, B.,Arikawa, Y.,Cramlett, J.,Dong, Q.,de Jong, R.,Feher, V.,Grimshaw, C.E.,Farrell, P.J.,Hoffman, I.D.,Jennings, A.,Jones, B.,Matuszkiewicz, J.,Miura, J.,Miyake, H.,Natala, S.R.,Shi, L.,Takahashi, M.,Taylor, E.,Wyrick, C.,Yano, J.,Zalevsky, J.,Nie, Z.
Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
Bioorg. Med. Chem. Lett., 26:5947-5950, 2016
Cited by
PubMed Abstract: Spleen Tyrosine Kinase (SYK) is a non-receptor cytoplasmic tyrosine kinase that is primarily expressed in hematopoietic cells. SYK is a key mediator for a variety of inflammatory cells, including B cells, mast cells, macrophages and neutrophils and therefore, an attractive approach for treatment of both inflammatory diseases and oncology indications. Using in house co-crystal structure information, and structure-based drug design, we designed and optimized a novel series of heteroaromatic pyrrolidinone SYK inhibitors resulting in the selection of the development candidate TAK-659. TAK-659 is currently undergoing Phase I clinical trials for advanced solid tumor and lymphoma malignancies, a Phase Ib study in advanced solid tumors in combination with nivolumab, and PhIb/II trials for relapsed/refractory AML.
PubMed: 27839918
DOI: 10.1016/j.bmcl.2016.10.087
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.77 Å)
Structure validation

238895

數據於2025-07-16公開中

PDB statisticsPDBj update infoContact PDBjnumon